Analysts See $0.28 EPS for Myriad Genetics, Inc. (MYGN)

October 13, 2018 - By olga

Myriad Genetics, Inc. (NASDAQ:MYGN) LogoInvestors sentiment decreased to 0.95 in Q2 2018. Its down 0.48, from 1.43 in 2018Q1. It is negative, as 25 investors sold Myriad Genetics, Inc. shares while 80 reduced holdings. 35 funds opened positions while 65 raised stakes. 71.11 million shares or 1.16% less from 71.94 million shares in 2018Q1 were reported.
Kbc Group Nv has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). Robecosam Ag stated it has 0.01% in Myriad Genetics, Inc. (NASDAQ:MYGN). Caisse De Depot Et Placement Du Quebec holds 0.02% or 265,819 shares in its portfolio. Systematic Mngmt Ltd Partnership accumulated 37,090 shares or 0.03% of the stock. Jefferies Gp Limited Liability Company holds 0% or 6,682 shares in its portfolio. Benjamin F Edwards Com Inc stated it has 0% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Comerica National Bank & Trust holds 0.04% in Myriad Genetics, Inc. (NASDAQ:MYGN) or 118,315 shares. Mason Street Limited Liability Corp owns 20,187 shares. Stifel Fincl Corp accumulated 57,068 shares. Louisiana State Employees Retirement Sys reported 31,300 shares. Mitsubishi Ufj Trust And Banking holds 496,629 shares. Taylor Frigon Ltd Liability holds 1.27% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN) for 46,856 shares. Cibc World has invested 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). California State Teachers Retirement Sys has 0.01% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Clarivest Asset Management Limited has 39,111 shares.

Since May 21, 2018, it had 0 insider buys, and 13 insider sales for $22.83 million activity. HENDERSON JOHN T sold $1.26 million worth of Myriad Genetics, Inc. (NASDAQ:MYGN) on Wednesday, July 11. Another trade for 60,000 shares valued at $2.41 million was made by LANCHBURY JERRY S on Monday, June 18. $3.42M worth of stock was sold by Capone Mark Christopher on Wednesday, May 30. 10,000 shares were sold by LANGER DENNIS, worth $379,245. GILBERT WALTER PHD sold 30,000 shares worth $1.19M.

Analysts expect Myriad Genetics, Inc. (NASDAQ:MYGN) to report $0.28 EPS on November, 6.They anticipate $0.02 EPS change or 7.69 % from last quarter’s $0.26 EPS. MYGN’s profit would be $20.92 million giving it 38.84 P/E if the $0.28 EPS is correct. After having $0.38 EPS previously, Myriad Genetics, Inc.’s analysts see -26.32 % EPS growth. The stock decreased 0.43% or $0.19 during the last trading session, reaching $43.5. About 877,995 shares traded or 20.63% up from the average. Myriad Genetics, Inc. (NASDAQ:MYGN) has risen 45.52% since October 14, 2017 and is uptrending. It has outperformed by 29.90% the S&P500.

Myriad Genetics, Inc. (NASDAQ:MYGN) Ratings Coverage

Among 5 analysts covering Myriad Genetics (NASDAQ:MYGN), 2 have Buy rating, 2 Sell and 1 Hold. Therefore 40% are positive. Myriad Genetics had 12 analyst reports since May 9, 2018 according to SRatingsIntel. The firm earned “Overweight” rating on Wednesday, October 10 by PiperJaffray. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Overweight” rating by Morgan Stanley on Wednesday, August 22. As per Wednesday, August 22, the company rating was maintained by Barclays Capital. The company was maintained on Wednesday, August 22 by Bank of America. As per Tuesday, May 29, the company rating was maintained by Leerink Swann. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) earned “Underperform” rating by Bank of America on Monday, July 16. The rating was downgraded by Barclays Capital to “Underweight” on Wednesday, September 5. The firm earned “Market Perform” rating on Tuesday, August 28 by Leerink Swann. The firm earned “Overweight” rating on Wednesday, October 10 by Morgan Stanley. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, May 9.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $3.25 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It has a 23.9 P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

More notable recent Myriad Genetics, Inc. (NASDAQ:MYGN) news were published by: Seekingalpha.com which released: “Key events next week – healthcare” on October 12, 2018, also Globenewswire.com with their article: “Detailed Research: Economic Perspectives on MTS, Delek US, Alarm, Strongbridge Biopharma, Myriad Genetics, and …” published on October 09, 2018, Globenewswire.com published: “Myriad Announces New GeneSight® Study Published in Personalized Medicine” on September 26, 2018. More interesting news about Myriad Genetics, Inc. (NASDAQ:MYGN) were released by: Seekingalpha.com and their article: “Myriad announces new laboratory agreement with Pfizer” published on October 10, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Top Upgrades, Downgrades For October 10, 2018” with publication date: October 10, 2018.

Myriad Genetics, Inc. (NASDAQ:MYGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>